Effect of omalizumab on inflammatory markers in COVID-19: an exploratory analysis of the COVID-19 immunologic antiviral therapy with omalizumab (CIAO) trial
Although limited by a small sample size, these results suggest that omalizumab's potential benefit in COVID-19 may be mediated independently of modulation of the measured serum biomarkers. Further studies are needed to investigate omalizumab's mechanism of action in COVID-19.
Authors
- Duncan Lejtenyi
- Shirin Golchi (ORCID: https://orcid.org/0000-0003-3382-9563)
- Elena Netchiporouk (ORCID: https://orcid.org/0000-0002-6692-7787)
- Connor Prosty (ORCID: https://orcid.org/0000-0001-6790-220X)
- Jennifer Tsang (ORCID: https://orcid.org/0000-0002-1809-0505)
- Michelle Le (ORCID: https://orcid.org/0000-0002-9393-0922)
- Todd C. Lee (ORCID: https://orcid.org/0000-0002-2267-4239)
- Srinivas Murthy (ORCID: https://orcid.org/0000-0002-9476-839X)
- Elham Rahme (ORCID: https://orcid.org/0000-0002-4168-4993)
- Maxime Cormier (ORCID: https://orcid.org/0000-0003-4608-6690)
- Moshe Ben‐Shoshan (ORCID: https://orcid.org/0000-0001-9083-1518)
- Nandini Dendukuri (ORCID: https://orcid.org/0000-0002-2330-0976)
- Yang Lu
- Robert Fowler (ORCID: https://orcid.org/0000-0002-1002-2989)
- Lauren Khoury (ORCID: https://orcid.org/0009-0003-7491-9386)
- M.-L. Cheng
Institutions
- Sunnybrook Health Science Centre (CA)
- University of British Columbia (CA)
- Montreal Children's Hospital (CA)
- Health Sciences Centre (CA)
- Niagara Health System (CA)
- McGill University (CA)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2024-11-19
- DOI
- https://doi.org/10.3389/fmed.2024.1437322
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- McGill University Health Centre